Researchers at the University of Illinois found that lunasin binds to a specific receptor in highly metastatic colon cancer cells, preventing them from attaching to the liver. Almost all colon cancer deaths involve the cancer spreading to the liver.
Specifically, combining lunasin with the chemotherapy drug oxaliplatin resulted in a six-fold reduction in the number of new tumor sites.
Related Articles on Colon Cancer:
High Levels of Alcohol Consumption Increase Risk of Colon Cancer
Study: MRI Helps Predict Survival of Rectal Cancer Patients
First Endoscopic Suturing Performed on Large Polyp Resection
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
